Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$16.92 USD

16.92
1,422,417

-0.30 (-1.74%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $16.90 -0.02 (-0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (98 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Zacks.com featured highlights Kronos, AMN Healthcare Services and Sanderson Farms

by Zacks Equity Research

Kronos, AMN Healthcare Services and Sanderson Farms have been highlighted in this Screen of the Week article.

Zacks Equity Research

AMN Healthcare Services (AMN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

AMN Healthcare Services (AMN) closed at $99.34 in the latest trading session, marking a +1.03% move from the prior day.

Zacks Equity Research

Here's Why You Should Hold on to DaVita (DVA) Stock For Now

by Zacks Equity Research

Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care and impressive overseas growth.

Zacks Equity Research

LabCorp (LH) Gets FDA Nod for VirSeq SARS-CoV-2 NGS Test

by Zacks Equity Research

LabCorp's (LH) VirSeq SARS-CoV-2 NGS Test can detect specific SARS-CoV-2 strains to help health care providers make appropriate patient treatment decisions.

Zacks Equity Research

Here's Why You Should Hold on to DexCom (DXCM) Stock Now

by Zacks Equity Research

DexCom (DXCM) continues to benefit from a solid product portfolio and a strong international presence. However, supply constraints remain a woe.

Zacks Equity Research

Bruker (BRKR) BSI & BEST Arms Drive Growth Amid Competition

by Zacks Equity Research

Bruker (BRKR) Nano Group's microelectronics and semiconductor metrology tools continue to perform well with ongoing strength in bookings and backlog.

Zacks Equity Research

Walgreens (WBA) Starts COVID Jabs for 3-Year Olds & Above

by Zacks Equity Research

Walgreens Boots (WBA) continues to serve communities with COVID testing and vaccinations to fight the pandemic.

Nilanjan Choudhury headshot

Market Crash Worries? Try 3 Relative Price Strength Stocks

by Nilanjan Choudhury

Kronos Worldwide (KRO), AMN Healthcare Services (AMN) and Sanderson Farms (SAFM) are three stocks with explosive relative price strength.

Zacks Equity Research

AMN Healthcare Services (AMN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

AMN Healthcare Services (AMN) closed the most recent trading day at $99.34, moving +1.03% from the previous trading session.

Zacks Equity Research

Here's Why You Should Invest in Bio-Rad (BIO) Stock Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad's (BIO) strong growth in its key product lines across several geographies.

Zacks Equity Research

Here's Why You Should Hold on to Abiomed (ABMD) Stock For Now

by Zacks Equity Research

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Zacks Equity Research

Henry Schein (HSIC) Global Dental Arm Rebounds Amid Cost Woes

by Zacks Equity Research

Henry Schein's (HSIC) widespread network and channel mix along with favorable long-term trends in the dental business look encouraging.

Zacks Equity Research

Hologic (HOLX) New Products Aid Growth, Margin Pressure Stays

by Zacks Equity Research

Hologic's (HOLX) core molecular diagnostics franchise is growing driven by strong uptake in newer assays such as vaginitis panel and menu within the virology product line.

Zacks Equity Research

PerkinElmer's (PKI) Arm Introduces Two CE-Marked Assays

by Zacks Equity Research

PerkinElmer's (PKI) company launches two CE-marked antibody tests that can support the analysis of the immune response to COVID-19.

Zacks Equity Research

Bruker (BRKR) Debuts Module on Ultima Multiphoton Microscopes

by Zacks Equity Research

Bruker's (BRKR) NeuraLight 3D Ultra module offers revolutionary 3D holographic photostimulation to support neuroscience and optogenetics research applications.

Zacks Equity Research

Here's Why You Should Hold on to Surmodics (SRDX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.

Zacks Equity Research

West Pharmaceutical's (WST) Syringe System to Improve Outcome

by Zacks Equity Research

West Pharmaceutical's (WST) new CZ syringe system size is expected to enable a simpler patient experience and aid pharmaceutical companies in providing better access to their products.

Zacks Equity Research

Here's Why You Should Retain West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

Zacks Equity Research

How Much Upside is Left in AMN Healthcare (AMN)? Wall Street Analysts Think 32%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 32% in AMN Healthcare (AMN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

What's in Store for Patterson Companies' (PDCO) Q4 Earnings?

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect improvement at the Animal Health segment.

Zacks Equity Research

Boston Scientific (BSX) to Broaden Stent Portfolio With Buyout

by Zacks Equity Research

According to Boston Scientific (BSX), M.I.Tech's product offerings complement the company's existing stent portfolio, including the differentiated AXIOS Stent and Electrocautery Enhanced Delivery System.

Zacks Equity Research

3 Reasons Why Growth Investors Shouldn't Overlook AMN Healthcare (AMN)

by Zacks Equity Research

AMN Healthcare (AMN) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

ResMed (RMD) Inks Deal to Acquire MEDIFOX DAN in Germany

by Zacks Equity Research

ResMed's (RMD) acquisition of a renowned out-of-hospital software solutions company is expected to strengthen its SaaS business.

Zacks Equity Research

BD's (BDX) Latest Collaboration to Enhance Patient Care

by Zacks Equity Research

BD's (BDX) new partnership is expected to increase efficiency for new clinical trials, generate evidence, support new claims for its products and streamline medical device regulatory submissions.

Zacks Equity Research

Here's Why You Should Hold Quest Diagnostics (DGX) Stock Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) owing to a strong recovery in its base business and encouraging 2022 guidance.